Form 4: Tenax Therapeutics Director Declan Doogan Reports Significant Stock Option Grant

Tenax Therapeutics, Inc. Director Declan Doogan reported the acquisition of 80,000 stock options with an exercise price of $5.75, effective July 1, 2025, as part of changes in his beneficial ownership.

Summary

• Declan Doogan, a Director of Tenax Therapeutics, Inc. (TENX), reported changes in his beneficial ownership of company securities.
• On July 1, 2025, Mr. Doogan acquired 80,000 stock options with an exercise price of $5.75. These options become exercisable on the same date and expire on July 1, 2035.
• Following this transaction, Mr. Doogan directly beneficially owns 2,274 shares of Tenax Therapeutics common stock.
• His total direct beneficial ownership of derivative securities includes the newly acquired 80,000 stock options, along with previously held options: 4 options exercisable at $3,200 (exercisable from June 10, 2022, expiring June 10, 2031), 4 options exercisable at $992 (exercisable from June 9, 2023, expiring June 9, 2032), and 100,000 options exercisable at $5.94 (exercisable from December 10, 2025, expiring December 10, 2034).

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally viewed as a neutral to slightly positive signal, indicating alignment of interests with future company performance, though it does not reflect operational results.

Positives

• The grant of 80,000 stock options to a director aligns management's interests with shareholder value creation, as the options gain value if the stock price increases above the exercise price of $5.75.

Risks

• Potential future dilution if the stock options are exercised, increasing the number of outstanding shares.

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not provide forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• Not applicable, as this filing reports individual insider transactions rather than company performance metrics that can be benchmarked against industry standards or competitors.

Related Party Transactions

• This Form 4 reports an insider transaction (stock option grant to a director), which is a form of related party dealing, but no other specific related party transactions are detailed.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised; alignment of director's interests with shareholder value.

Key Dates

Keywords

Tenax Therapeutics, TENX, Form 4, insider transaction, stock options, beneficial ownership, director, equity compensation